Biochips Based In-vitro Diagnostics Market Size, Share and Global Trend by Application (DNA applications, Lab-on-chip applications, Protein micro-array applications, Other array applications), By End users (Hospitals & Clinics, Research Institutions, Diagnostic Centers), and Regional Forecast, 2024-2032

A Biochip refers to the variety or range of multiple tests contained on a single chip which leads to the increase in the capabilities of the analysis undertaken, which increases the efficiency of the tests carried out. In-vitro diagnostics is defined as the diagnostics which tests or analyzes a sample of bodily fluids or tissues such as blood glucose testing, electrolyte levels in the blood, testing for calcium, liver function and genetic testing amongst others. Thus, a biochip based in-vitro diagnostics refers to the biochips containing multiple in-vitro diagnostics.

The market for the biochips based in-vitro diagnostics are growing because of the increased demand for the efficient and swift diagnostic procedures for the diagnosis, treatment and management of various acute and chronic diseases. There have been a series of considerable investments for the serious research & development of protein microarrays, DNA microarrays and lab-on-a-chips. 

The growth in the number of products in the various stages of R&D combined with the increasing demand for swift and efficient diagnostics and also, the increasing demand for minimally invasive technologies are expected to further drive the market growth. For instance, the increasing investments in a number of biochips based in-vitro diagnostics such as protein microarrays are expected to drive the market growth at a considerable rate.

The factor that is expected to inhibit the growth of the market is the complex manufacturing process of the biochips based in-vitro diagnostics, for instance during the manufacturing process of protein microarrays, it was discovered that the proteins are extremely difficult to handle and as an outcome, the protein microarrays are yet to be widely available in the market. Regulatory and clinical hurdles might also impact the growth of the market due to delays in product approvals and the apprehension of the clinicians to use them in the daily usage yet. 

Key Players Covered 

Some of the major companies that are present in the global Biochips Based In-vitro Diagnostics market Agilent Technologies, Inc., SCHOTT AG, Thermo Fisher Scientific, Randox Laboratories Ltd. and Greiner Bio One International GmbH and other players.

SEGMENTATION

At present, DNA applications, lab-on-a-chip applications and protein micro-array applications accounts for the largest proportion of the market and this is not expected to change in the forecast period due to the increasing investment efforts and the extensive R&D efforts and clinical trials being conducted in the segment. 

Key Insights 

• Overview of technological advancements


• Regulatory scenario by key countries


• New product launches


• Overview of new applications of Biochips Based In-vitro Diagnostics  

Regional Analysis:

The global Biochips Based In-vitro Diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe are the two largest markets for Biochips Based In-vitro Diagnostics at present and they are expected to account for a large proportion of the market in the forecast period as well. North America had the highest market share due to the increasing applications of the biochips in DNA testing and other applications and the biochips will gain some applications such as nucleic acid biomarkers due to the increased speed and accuracy. In Asia Pacific, Japan is expected to provide the largest market opportunity. This is primarily due to the increased research initiatives, in some instances publicly funded, conducted in Japan also combined with a high proportion of ageing population, where there is a greater demand for diagnostic procedures. 

Key Industry Developments

• In March 2019, Axbio Inc. announced the successful development of the company’s In-Vitro Diagnostic Bio-CMOS IC based on the collaborator TowerJazz’s Advanced 300mm 65nm RFCMOS Platform. The peer reviewed journal, The Lancet, published by Elsevier announced in March, 2019 that ongoing R&D is being conducted for the rapid and accurate diagnosis of the respiratory disease, pertussis, on a point-on-care biochip.


•  


• In April 2018, Randox Laboratories and Bosch collaborated on a product called Vivalytic, a point of care testing for respiratory and sexually transmitted infections, which was developed using Randox’s patented biochip array technology


• In November 2017, researchers at the Universidad Politécnica de Madrid (UPM), announced the development of an optical biosensor with an improved method of read-out that allows for the in vitro detection of a biological material. This optical biosensor was developed as a Point-of-Care (PoC) Optical Reading Device.